BioInvent International Past Earnings Performance
Past criteria checks 0/6
BioInvent International's earnings have been declining at an average annual rate of -7.3%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 32.6% per year.
Key information
-7.3%
Earnings growth rate
24.9%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 32.6% |
| Return on equity | -2.5% |
| Net Margin | -13.8% |
| Next Earnings Update | 22 Feb 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BioInvent International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 310 | -43 | 47 | 311 |
| 30 Jun 22 | 295 | -42 | 45 | 291 |
| 31 Mar 22 | 30 | -266 | 43 | 254 |
| 31 Dec 21 | 19 | -278 | 39 | 258 |
| 30 Sep 21 | 113 | -171 | 37 | 248 |
| 30 Jun 21 | 126 | -141 | 37 | 232 |
| 31 Mar 21 | 137 | -123 | 34 | 226 |
| 31 Dec 20 | 147 | -76 | 32 | 191 |
| 30 Sep 20 | 74 | -146 | 30 | 191 |
| 30 Jun 20 | 76 | -150 | 30 | 198 |
| 31 Mar 20 | 93 | -144 | 30 | 209 |
| 31 Dec 19 | 94 | -139 | 29 | 208 |
| 30 Sep 19 | 79 | -130 | 28 | 190 |
| 30 Jun 19 | 68 | -116 | 27 | 165 |
| 31 Mar 19 | 45 | -126 | 27 | 153 |
| 31 Dec 18 | 39 | -123 | 28 | 140 |
| 30 Sep 18 | 42 | -124 | 34 | 136 |
| 30 Jun 18 | 42 | -123 | 36 | 133 |
| 31 Mar 18 | 43 | -103 | 37 | 114 |
| 31 Dec 17 | 45 | -101 | 39 | 110 |
| 30 Sep 17 | 62 | -75 | 39 | 98 |
| 30 Jun 17 | 56 | -82 | 39 | 99 |
| 31 Mar 17 | 55 | -85 | 39 | 102 |
| 31 Dec 16 | 71 | -63 | 36 | 99 |
| 30 Sep 16 | 50 | -76 | 32 | 100 |
| 30 Jun 16 | 51 | -70 | 32 | 96 |
| 31 Mar 16 | 45 | -69 | 31 | 88 |
Quality Earnings: BINVS is currently unprofitable.
Growing Profit Margin: BINVS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BINVS is unprofitable, and losses have increased over the past 5 years at a rate of 7.3% per year.
Accelerating Growth: Unable to compare BINVS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BINVS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: BINVS has a negative Return on Equity (-2.55%), as it is currently unprofitable.